Stockholm – April 28, 2026 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the 2025 Annual Report has been published.
“2025 was a year of progress for Oncopeptides. As we celebrated our 25th anniversary, we transitioned from a foundational launch phase into a period of growth, scientific validation, and strategic clarity,” says Sofia Heigis, CEO of Oncopeptides. “Our flagship drug, Pepaxti, is no longer just “newly launched”— it is a growing treatment delivering triple-digit growth and life-changing. The most exciting development of the year lies in our potential ability to deploy our validated PDC platform into new, high-value indications.”
The Annual Report for 2025 is available in PDF format at Oncopeptides’ web site under financial reports.